Cara Therapeutics
Biotechnology company focused on developing therapeutics to treat diseases associated with pain and inflammation.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $40.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 1378 % | 48 % | 579 % | (83 %) | 82 % | (50 %) | (66 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (572 %) | (562 %) | 4 % | (387 %) | (209 %) | (561 %) | (698 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (550 %) | (535 %) | 6 % | (384 %) | (204 %) | (565 %) | (993 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 561 % | 572 % | 80 % | 359 % | 219 % | 518 % | 460 % |
Source: Company filings or news article
Related Content
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for the treatment of pruritus (itching) and pain. The company primarily serves patients suffering from chronic kidney disease (CKD), chronic liver disease (CLD), and atopic dermatitis (AD), which are conditions often associated with severe pruritus. Operating in the biopharmaceutical market, Cara Therapeutics employs a business model centered around research and development (R&D) of new pharmaceutical products, followed by clinical trials and regulatory approvals. Revenue is generated through partnerships, licensing agreements, and eventual product sales upon market approval. The company aims to address significant unmet medical needs by providing effective and safe treatments for conditions that currently have limited therapeutic options.
Keywords: biotechnology, pruritus, pain management, chronic kidney disease, chronic liver disease, atopic dermatitis, clinical trials, pharmaceutical development, innovative therapies, biopharmaceutical market.
Tech stack
Investments by Cara Therapeutics
Edit